⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2026ESMO rare cancers.Open Access

292P Exploring HER3; A potentially targetable biomarker in rare metaplastic breast cancers

Nour Abuhadra T. Adeyelu Fresia Pareja Sarat Chandarlapaty George Plitas A. Elliott T.A. Traina M. Robson Theodore Nicolaides S. Graff M. Lustberg L. Norton G. Sledge G. Montagna

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to explore the role of HER3 as a potential targetable biomarker in rare metaplastic breast cancers.
Examined data from patients treated with the CSF-1R inhibitor pimi.
Monitored adverse events (AEs) including laboratory abnormalities and clinical symptoms.
Analyzed the duration and onset of AEs.
Patients experienced manageable and reversible toxicities.
Pimi showed sustained antitumor activity with few treatment discontinuations related to AEs.
Common AEs included laboratory abnormalities and clinical edema.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Analysis explores HER3 as a biomarker for metaplastic breast cancers, suggesting potential treatment pathways.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abuhadra et al. (2026) studied this question.

synapsesocial.com/papers/69b2577f96eeacc4fcec6399 https://doi.org/10.1016/j.esmorc.2026.100217

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1290P Sarcomatous transformation in germ cell tumors arises through early clonal divergence rather than linear progressionClinical Trial · 2026
2291P Whole-body MRI screening for Li-Fraumeni syndrome: The Irish experienceClinical Trial · 2026
3Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.Human Clinical Trial · 2026
4Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.Late-Phase Clinical Trial · 2026
5Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.RCT · 2026
6Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast DiscussionBlinded Clinical Trial · 2026
7289P Manageable longer-term safety with the highly-selective colony stimulating factor-1 receptor (CSF-1R) inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT) in the global MANEUVER trialHuman Clinical Trial · 2026
8Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trialClinical Trial · 2026
9Palliative systemic chemotherapy in peritoneal mesothelioma: a retrospective efficacy analysis of the RENAPE databaseESMO rare cancers. · 2026
10Using liver-directed therapies as backbone for combination-treatments in metastatic uveal melanomaESMO rare cancers. · 2026

More from ESMO rare cancers.

More from Yale University

More from Memorial Sloan Kettering Cancer Center

More from Brown University

More from Caris Life Sciences (United States)